[en] The aim of this multicenter, randomized, double-blind, 8-week study was to compare the antidepressant efficacy and tolerability of mirtazapine and venlafaxine in the treatment of hospitalized patients with DSM-IV diagnosis of severe depressive episode with melancholic features. Patients with a baseline score of ≥ 25 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17) were randomly assigned to receive treatment with either mirtazapine (N = 78, 15-60 mg/day) or venlafaxine (N = 79, 75-375 mg/day, twice a day) in a rapid up-titration schedule. Efficacy was assessed with the Montgomery-Åsberg Depression Rating Scale (MADRS), HAM-D-17, and Clinical Global Impression scale, and quality of life was assessed with the Quality of Life, Enjoyment, and Satisfaction Questionnaire and Quality of Life in Depression Scale. Tolerability was assessed with the Utvalg for Kliniske Undersogelser (UKU) side effect scale and by reporting adverse events. Both drugs were effective in reducing overall symptoms of depression, showing substantial reductions in group mean MADRS scores (-20.1 for mirtazapine and -17.5 for venlafaxine) and HAM-D-17 scores (-17.1 for mirtazapine and -14.6 for venlafaxine) at the end of the treatment. Although not statistically significant, at all assessment times higher percentages of patients treated with mirtazapine were classified as responders (≥50% reduction) on the HAM-D (at endpoint, 62% vs. 52%) and MADRS (at endpoint: 64% vs. 58%). Likewise were the percentages of remitters (HAM-D score ≤7; MADRS score ≤12) also higher in the mirtazapine group. A statistically significant difference favoring mirtazapine was found on the HAM-D Sleep Disturbance factor at all assessment points (p ≤ 0.03). Both treatments were well tolerated. Although slightly more subjects treated with mirtazapine reported at least one adverse event, a statistically significantly higher percentage of patients treated with venlafaxine (15.3%) than mirtazapine (5.1%) dropped out because of adverse events (p = 0.037). Quality of life improved in both treatment groups. In this study, treatment with mirtazapine resulted in a trend toward more responders and remitters than treatment with venlafaxine and in significantly fewer dropouts as a result of adverse events.
Disciplines :
Psychiatry
Author, co-author :
Guelfi, Julien Daniel; Hôpital Paul Brousse, Villejuif, France, Sainte Anne, CMME, 100 rue de la Santé, 75674 Paris Cedex 14, France
Amsterdam J.D. (1998) Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J Psychopharmacol 12(SUPPL. B).
Guelfi J.D., White C., Hackett D. (1995) Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 56:450-458.
Clerc G.E., Ruimy P., Verdeau-Paillès J. (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol , The Venlafaxine French Inpatient Study Group; 9:139-140.
Holm K.J., Markham A. (1999) Mirtazapine: A review of its use in major depression. Drugs 57:607-631.
Wheatley D.P., Van Moffaert M., Timmerman L. (1998) Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry , Mirtazapine-Fluoxetine Study Group; 59:306-312.
Leinonen E., Skarstein J., Behnke K. (1999) Efficacy and tolerability of mirtazapine versus citalopram: A double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol , Nordic Antidepressant Study Group; 14:329-337.
Benkert O., Szegedi A., Kohnen R. (2000) Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 61:656-663.
Hamilton M. (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
Montgomery S.A., Åsberg M. (1979) A new depression rating scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
Guy W. ECDEU assessment manual for psychopharmacology, revised , Department of Health, Education, and Welfare, Publication no. (ADM) 76-338. Rockville, MD: National Institutes of Mental Health; 1976, 218-222.
Endicott J., Nee J., Harrison W. (1993) Quality of life, enjoyment and satisfaction questionnaire: A new measure. Psychopharmacol Bull 29:321-326.
Hunt S.M., McKenna S.P. (1992) The QLDS: A scale for the measurement of quality of life in depression. Health Policy 22:307-319.
Lingjaerde O., Ahlfors U.G., Bech P. (1987) The UKU side effect rating scale. Acta Psychiatr Scand 76(SUPPL. 334):1-100.
Adverse reactions terminology (WHO-ART), Geneva: World Health Organization; 1997.
Koch G.C., Carr J. (1990) Categorical data analysis., Berry DA, ed. Statistical methodology in pharmaceutical sciences. New York: Marcel Dekker; 389-473.
Dierick M. (1997) A review of the efficacy and tolerability of venlafaxine. Eur Psychiatry 12(SUPPL. 4).
Kocsis J.H., Croughan J.L., Katz M.M. (1990) Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression. Am J Psychiatry 147:621-624.
Keller M.B. Diagnostic issues and clinical course of unipolar illness. Review of psychiatry , Washington, DC: American Psychiatric Press; 1988, 7:188-212.
Prien R.F. Somatic treatment of unipolar depressive disorder. Review of psychiatry , Washington, DC: American Psychiatric Press; 1988, 7:213-234.
Hirschfeld R.M.A. (1999) Efficacy of SSRIs and newer antidepressants in severe depression: Comparison with TCAs. J Clin Psychiatry 60:326-335.
(1986) Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicentre study. Psychopharmacology 90:131-138.
(1990) Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord , Danish University Antidepressant Group; 18:289-299.